These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 235636

  • 1. The effect of liver disease in man on the disposition of phenobarbital.
    Alvin J, McHorse T, Hoyumpa A, Bush MT, Schenker S.
    J Pharmacol Exp Ther; 1975 Jan; 192(1):224-35. PubMed ID: 235636
    [Abstract] [Full Text] [Related]

  • 2. Metabolic fate of phenobarbital. A quantitative study of p-hydroxyphenobarbital elimination in man.
    Whyte MP, Dekaban AS.
    Drug Metab Dispos; 1977 Jan; 5(1):63-70. PubMed ID: 13977
    [Abstract] [Full Text] [Related]

  • 3. The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
    Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR.
    J Clin Invest; 1975 Feb; 55(2):347-59. PubMed ID: 1127104
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Altered hepatobiliary disposition of acetaminophen metabolites after phenobarbital pretreatment and renal ligation: evidence for impaired biliary excretion and a diffusional barrier.
    Brouwer KL, Jones JA.
    J Pharmacol Exp Ther; 1990 Feb; 252(2):657-64. PubMed ID: 2313593
    [Abstract] [Full Text] [Related]

  • 6. Clinical findings in patients with hepatitis and abnormal bile duct epithelium.
    Christoffersen P, Poulsen H, Winkler K.
    Scand J Gastroenterol; 1970 Feb; 5(2):117-21. PubMed ID: 5429872
    [No Abstract] [Full Text] [Related]

  • 7. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.
    Wensing G, Lotterer E, Link I, Hahn EG, Fleig WE.
    Hepatology; 1997 Nov; 26(5):1149-55. PubMed ID: 9362355
    [Abstract] [Full Text] [Related]

  • 8. The effects of acute infectious hepatitis and cirrhosis of the liver on the nonerythropoietic component of early bilirubin.
    Tarao K, Fukushima K, Endo O, Kamiyo A.
    J Lab Clin Med; 1976 Feb; 87(2):240-50. PubMed ID: 1245790
    [Abstract] [Full Text] [Related]

  • 9. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [Abstract] [Full Text] [Related]

  • 10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 11. [Changes in renal function in patients with severe hepatitis and liver cancer with cirrhosis during orthotopic liver transplantation].
    Li XY, Hei ZQ, Li SR, Shen N.
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Jul; 19(7):386-9. PubMed ID: 17631701
    [Abstract] [Full Text] [Related]

  • 12. Impaired biliary excretion of acetaminophen glucuronide in the isolated perfused rat liver after acute phenobarbital treatment and in vivo phenobarbital pretreatment.
    Studenberg SD, Brouwer KL.
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1022-7. PubMed ID: 1602370
    [Abstract] [Full Text] [Related]

  • 13. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease.
    DeVane CL, Laizure SC, Stewart JT, Kolts BE, Ryerson EG, Miller RL, Lai AA.
    J Clin Psychopharmacol; 1990 Oct; 10(5):328-32. PubMed ID: 2124217
    [Abstract] [Full Text] [Related]

  • 14. Urinary kallikrein excretion in chronic liver disease and effect of indomethacin.
    Kawasaki H, Murawaki Y, Hirayama C.
    Am J Gastroenterol; 1986 Jan; 81(1):67-70. PubMed ID: 3510529
    [Abstract] [Full Text] [Related]

  • 15. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy.
    Rühl R, Seidensticker M, Peters N, Mohnike K, Bornschein J, Schütte K, Amthauer H, Malfertheiner P, Pech M, Ricke J.
    Dig Dis; 2009 Jan; 27(2):189-99. PubMed ID: 19546558
    [Abstract] [Full Text] [Related]

  • 16. Dipyrone metabolism in liver disease.
    Zylber-Katz E, Caraco Y, Granit L, Levy M.
    Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
    [Abstract] [Full Text] [Related]

  • 17. The effect of cirrhosis on the disposition and elimination of clindamycin.
    Avant GR, Schenker S, Alford RH.
    Am J Dig Dis; 1975 Mar; 20(3):223-30. PubMed ID: 1168411
    [Abstract] [Full Text] [Related]

  • 18. Half-life time or clearance of indocyanine green in patients with liver disease.
    Gilmore IT, Marigold JH, Thompson RP.
    Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
    [Abstract] [Full Text] [Related]

  • 19. Corticosteroid-induced changes in urea metabolism in patients with hepatocellular disease.
    Jones EA, Cain GD, Dickinson G.
    Gastroenterology; 1972 Apr; 62(4):612-7. PubMed ID: 5020873
    [No Abstract] [Full Text] [Related]

  • 20. [Hepatic clearance of 99mTc-p-butyl HIDA in liver diseases. Correlations with routine hematochemical parameters of liver function].
    Custro N, De Francisci MC, Patanella I, Scafidi V, Indovina I.
    Minerva Med; 1984 Nov 03; 75(42):2527-32. PubMed ID: 6083507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.